NASDAQ:ELDN Eledon Pharmaceuticals Q2 2026 Earnings Report $3.28 -0.07 (-1.94%) As of 12:22 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eledon Pharmaceuticals EPS ResultsActual EPS-$0.27Consensus EPS -$0.16Beat/MissMissed by -$0.11One Year Ago EPSN/AEledon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEledon Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETUpcoming EarningsEledon Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eledon Pharmaceuticals Earnings HeadlinesEledon Pharmaceuticals (NASDAQ:ELDN) Downgraded by Wall Street Zen to "Strong Sell"August 23, 2026 | americanbankingnews.comEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 13, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 27 at 1:00 AM | Porter & Company (Ad)Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant InvestingJuly 22, 2026 | tipranks.comDrug to prevent organ rejection after kidney transplant tops standard treatment in trialJune 24, 2026 | msn.comEledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with ...June 22, 2026 | finance.yahoo.comSee More Eledon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email. Email Address About Eledon PharmaceuticalsEledon Pharmaceuticals (NASDAQ:ELDN) (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders. Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. Its lead candidate has advanced into initial human trials, and additional assets are in IND-enabling studies. To support development, the company collaborates with academic research institutions and specialty contract development organizations, drawing on external expertise for pharmacology, toxicology and clinical trial execution. Based in the United States with operations in Europe, Eledon Pharmaceuticals conducts multi-center studies across North America and the EMEA region. The company’s leadership team brings together experienced drug development professionals, clinical operations specialists and regulatory experts, positioning Eledon to advance its portfolio toward late-stage trials and eventual commercialization. View Eledon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout IsMarvell’s Big AI Test Comes One Day After NVIDIA’s Blowout QuarterWhen Unusual Volume Isn't Noise: 3 Small-Caps Sending SignalsSemtech Stock Rallies on Strong Q2 Results and Raised GuidanceWilliams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaiseJ.M. Smucker’s Rally Nears a Key Test: Is a Full Recovery Ahead?Photronics Is Quietly Becoming a Key Winner From the AI Boom Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
